SAM
CLDX icon

Silphium Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Silphium Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,205
Closed -$77.1K – 121
2018
Q1 		$77.1K Hold
2,205
– – 0.04% 78
2017
Q4 		$93.9K Buy
+2,205
New +$94.5K 0.11% 52

Other funds holding CLDX

KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Silphium Asset Management's CLDX Position: Q2 2018 in Review

Silphium Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2018, closing a stake of 2,205 shares — an estimated $77.1K sold.

Silphium Asset Management first reported a position in CLDX in Q4 2017 and held it in 2 quarters. The position peaked at $93.9K in Q4 2017. 102 funds tracked by Wall St. Rank hold CLDX as of Q2 2018.

  • Silphium Asset Management reported no remaining Celldex Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Silphium Asset Management sold 2,205 Celldex Therapeutics shares in Q2 2018, an estimated $77.1K.
  • Silphium Asset Management first reported a position in Celldex Therapeutics in Q4 2017 and held it in 2 quarters.
  • Silphium Asset Management's Celldex Therapeutics position peaked at $93.9K in Q4 2017.
  • 102 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2018.

Based on Silphium Asset Management's 13F filing for Q2 2018, filed 30 Jan 2025.